Drug exposure during breastfeeding: a descriptive population-based cohort study with SIDIAP database Authors: Maria Giner-Soriano, Guim Arbona Ricart, Àurea Cartanyà-Hueso, Ainhoa Gomez-Lumbreras, Marta Lestón Vázquez, Rosa Morros, Cristina Vedia Published: 2025 ABSTRACT AbstractBackgroundThere is a gap in the knowledge of drug exposure during breastfeeding due to exclusion of lactating individuals from studies. It makes difficult to fully understand the implication of drug use while breastfeeding and potential risks to newborns. Breastfeeding information in the Electronic Health Records (EHR) may help us to increase this evidence. We aimed to describe drug exposure during breastfeeding in mothers of a cohort of mother-infant linked pairs in Catalonia, Spain.MethodsWe conducted a descriptive population-based cohort study including mother-infant linked pairs of infants born during 2010–2022. The data source was the Information System for Research in Primary Care (SIDIAP), including sociodemographic characteristics, comorbidities, prescribed and reimbursed drugs, and lactation registers. Lactation is registered in the infants’ EHR. We analyzed drug exposure from delivery up to 2, 4, 6 and 12 months afterwards. We described categorical variables by absolute frequency and percentage and continuous variables by mean and standard deviation.ResultsWe included 176,324 mother-infant pairs with lactation registers during the first year after birth. Breastfed infants decreased during the first year to 64,225 (36.4%). Drug exposure varied from 76,064 (43.1% of the lactating mothers) from delivery up to month 2, to 32,475 (21.9%), 17,396 (17.6%) and 20,433 (31.8%) at up to months 4, 6 and 12, respectively. The most dispensed drugs were iron (25%), folic acid (15.5%) and analgesics (17.8%). Paracetamol was the most frequent analgesic (89.7%), amoxicillin and fosfomycin were the most frequent antibiotics (92.4% and 89.4%), or ibuprofen the most frequent non-steroidal anti-inflammatory drug (75.6%).ConclusionsThe number of lactating and drug-exposed mothers decreased over time. Iron and supplements were the most used drugs, mainly during the first two months, probably due to continuation since pregnancy or post-partum anemia. Analgesics and penicillins were also frequent, which might be used for common acute conditions. Our main limitation is the potential underreporting of drug exposure due to lack of information on over-the-counter drugs.Trial registration“Drug use in pregnant and breastfeeding women. Outcomes in the health of the women and the offspring”, EUPAS47450, registered at the HMA-EMA Catalogues of real-world data sources and studies: https://catalogues.ema.europa.eu/node/3222/administrative-details.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13006-025-00797-3.Keywords: Breastfeeding, Lactation, Drug exposure, Electronic health records, Mother-child relation, Pharmacoepidemiology, Prevalence Background Pregnancy and breastfeeding are physiological process in females’ fertility life where there is a lack of comprehensive data on drug safety due to the exclusion of pregnant and lactating individuals from clinical trials and other studies for ethical reasons [1–4]. In 2015, the United States Food and Drug Administration (FDA) implemented the Pregnancy and Lactation Labelling Rule to assist in the prescription decision making process during pregnancy and lactation requiring a narrative description of the risks and clinical considerations of drugs differentiated into three sections: gestation (including childbirth), lactation and, reproductive potential in men and women [5, 6]. The European Medicines Agency establishes in its Good Practice Guide on Pharmacovigilance for specific populations – pregnant and breastfeeding women – that it is necessary to carry out post authorization observational safety studies on those drugs that cannot be discontinued during pregnancy, drugs to treat gestational/lactational diseases or drugs that in preclinical studies have shown some type of risk for the offspring [7]. Despite the warnings on the use of some drugs in pregnancy or breastfeeding, it is not always advisable to discontinue some chronic drug treatments due to an increased risk of disease complications in the mother or offspring [4, 8]. In Spain, the tool e-lactancia.org is widely used by healthcare professionals to search for information on drug exposure during breastfeeding and as providers seen it useful during the prescription process [9]. It classifies the drugs in one of four categories, according to their compatibility to be administered while breastfeeding [10]. The electronic health records in Catalonia (ECAP) [11] include the PREFASEG (Safe Pharmacological Prescription) tool in the prescription software, which alerts on drug-drug interactions, allergies, duplicated treatments and contraindications, and includes alerts related to pregnancy and lactation [12]. However, lactating individuals and their healthcare professionals often lack data to support their decisions on medication use. This gap in knowledge makes it challenging to fully understand the implication of drug use while breastfeeding and potential risks to newborns, as some drugs may pass into breast milk [8]. Breastfeeding information stored in the electronic health records (EHR) can be used for pharmacoepidemiology research [13, 14]. Some population-based studies have been conducted to fill in this gap, as healthcare databases offer numerous advantages when studying the utilization and safety of drugs during lactation [15–17]. As mother-infant linked information is available in our database, it is possible to study drug exposure in mothers during breastfeeding. For this reason, we aimed to describe drug exposure during breastfeeding in mothers of a cohort of mother-infant linked pairs in Catalonia, Spain. Methods Design and study populations Descriptive observational study using a population-based cohort of mother-infant linked pairs. The populations included mothers and infants with linked EHR. Study period We analyzed the information available for those mother-infant linked pairs for infants born from January 2010 to December 2022. Data source The study data source was SIDIAP, which captures clinical information of 5.8 million people from Catalonia, Spain [18, 19]. SIDIAP database is pseudonymized and contains information from different data sources: (1) EHR in primary health care of the Catalan Health Institute (approximately attending 75% of the Catalan population); including sociodemographic characteristics, comorbidities registered as International Classification of Diseases, 10th revision, Clinical Modification (ICD­10-CM) codes (Supplementary Table S1), [20] specialist referrals, clinical parameters, toxic habits (tobacco and alcohol consumption), sickness leave, date of death, laboratory test, pediatric visits, [21] and drug prescriptions issued in Primary Health Care, registered as Anatomical Therapeutic Chemical (ATC) classification system codes (Supplementary Table S2) [22]. (2) Sexual and reproductive healthcare (ASSIR) records, which is the EHR module used by gynecologists and midwives to register variables related with the sexual and reproductive health of women and follow-up of pregnancies. (3) Pharmacy invoice data corresponding to the Primary Care drug prescriptions, classified according to the ATC classification. [24] We have previously established an algorithm to identify pregnancy episodes, [23] and SIDIAP has previously established an algorithm that links mothers with their offspring [24]. This algorithm was applied to identify the mother-infant pairs of interest for this study. We included all children born in 2010–2022 linked to their mothers with lactation registers in their EHR. Variables Variables were retrieved from the mother-infant pairs as follows: Infants’ variables; sociodemographic variables (age and sex) and registers of lactation in the EHR during the first 12 months after birth. Lactation is registered during routine pediatric visits by the Primary Care pediatric team (pediatrician and pediatric nurse) [21]. Maternal variables; sociodemographic variables (age and MEDEA socioeconomic index [25]), comorbidities up to delivery date, pregnancy follow-up variables (e.g. gestational week, delivery procedures), drug exposure during the first year of breastfeeding. We analyzed drug exposure during lactation in four time periods after delivery: 0–2, 2–4, 4–6, and 6–12 months. Statistical analysis We described maternal and infant characteristics by absolute frequency and percentage categorical variables and by mean and standard deviation, and median and interquartile range continuous variables. In addition, we calculated the prevalences of drug use during breastfeeding in the four time intervals described above. Drugs used by at least 0.5% of mothers at any time points were described. Results We identified 176,324 mother-infant pairs with breastfeeding registers during the first year after birth in our study period (Fig. 1). Flowchart of study inclusion Infants receiving breast milk decreased progressively through the first year of life, from 176,324 to 148,413 (84.2%) during months 2 to 4, 98,635 (55.9%) during months 4 to 6, and 64,225 (36.4%) from months 6 to 12. The mean duration of the breastfeeding was 6.2 months (SD 3.8) and the median, 6.0 (IQR 3.0–9.0). The distribution of infants and their breastfeeding records from 2010 to 2022 is shown in Fig. 2. The proportion of breastfed infants for up to 2 months increased approximately from 2017 to 2022, while the proportion of infants receiving breastfeeding up to 4 months decreased. The proportions for the other two time-cuts are stable. The proportions in 2022 do not follow the same pattern due to the censoring of the end of study period. Distribution of infants of the mother-infant cohort by calendar year of birth and with breastfeeding registers at each time-cut Baseline mothers’ characteristics are described in Table 1. They had a mean age of 32.3 years (SD 5.5), their MEDEA socioeconomic index was rural for 25,765 of them (17.6%), and 65,823 (45.1%) lived in the least deprived urban areas. Smoking habit was registered during pregnancy or the previous 12 months only for 33,079 (18.8%) of the mothers, being 5,814 (17.6%) current smokers. Body mass index was registered during pregnancy or the previous 12 months only for 39,689 (22.5%) of the mothers and 19,003 of them (47.9%) overweight or obese. More than half of the mothers had at least one comorbidity (N = 96,635, 54.8%), psychiatric diagnoses were the most frequent ones (24.9%), followed by obesity (9.4%). More than half of the mothers were exposed to drugs 96,094 (54.5%) during the first year after delivery. The characteristics of the non-exposed and exposed mothers are shown in Supplementary Table S3. Table 1Baseline sociodemographic and clinical characteristics of mothers linked to infants receiving breast milk after birthVariablesBreastfeeding mothers, N = 176,324Age, years Mean, SD Median, IQR32.3 (5.5)32.7 [28.8, 36.1]Categorized, n (%) 12–14 15–24 25–29 30–34 25–39 ≥ 404 (0.0)14,805 (8.4)31,309 (17.8)59,422 (33.7)53,381 (30.3)17,403 (9.9)Smoking habits, n (%) Missing values Current smokers Ex-smokers Non-smokers143,245 (81.2)5,814 (3.3)9,065 (5.1)18,200 (10.3)MEDEA socioeconomic index, n (%) Missing values Rural Urban, quintiles 1–3 Urban, quintiles 4–530,253 (17.2)25,765 (17.6)65,823 (45.1)54,483 (37.3)Comorbidities, n (%) At least one diagnosis Psychiatric diagnoses Obesity Neoplasms Migraine Respiratory diseases Cardiovascular conditions Diabetes Epilepsy96,635 (54.8)43,972 (24.9)16,505 (9.4)10,252 (5.8)10,158 (5.8)8,718 (4.9)1,710 (1.0)1,693 (1.0)635 (0.4)BMI, kg/m2, n (%) Missing values < 18 (underweight) 18–25 (normal weight) 25–30 (overweight) > 30 (obesity)136,635 (77.5)1,291 (0.7)19,395 (11.0)11,826 (6.7)7,177 (4.1)Multiparous, n (%)37,533 (21.3)Gestational week at delivery, n (%) < 32 32–36 ≥ 371,507 (0.9)3,085 (1.7)171,732 (97.4)Exposure to drugs during anytime from birth to 12 months after, n (%)96,094 (54.5)SD: standard deviation. IQR: interquartile range MEDEA: socioeconomic index of one rural category and five urban categories/quintiles. BMI: body mass index Baseline sociodemographic and clinical characteristics of mothers linked to infants receiving breast milk after birth Mean, SD Median, IQR 32.3 (5.5) 32.7 [28.8, 36.1] 12–14 15–24 25–29 30–34 25–39 ≥ 40 4 (0.0) 14,805 (8.4) 31,309 (17.8) 59,422 (33.7) 53,381 (30.3) 17,403 (9.9) Missing values Current smokers Ex-smokers Non-smokers 143,245 (81.2) 5,814 (3.3) 9,065 (5.1) 18,200 (10.3) Missing values Rural Urban, quintiles 1–3 Urban, quintiles 4–5 30,253 (17.2) 25,765 (17.6) 65,823 (45.1) 54,483 (37.3) At least one diagnosis Psychiatric diagnoses Obesity Neoplasms Migraine Respiratory diseases Cardiovascular conditions Diabetes Epilepsy 96,635 (54.8) 43,972 (24.9) 16,505 (9.4) 10,252 (5.8) 10,158 (5.8) 8,718 (4.9) 1,710 (1.0) 1,693 (1.0) 635 (0.4) Missing values < 18 (underweight) 18–25 (normal weight) 25–30 (overweight) > 30 (obesity) 136,635 (77.5) 1,291 (0.7) 19,395 (11.0) 11,826 (6.7) 7,177 (4.1) < 32 32–36 ≥ 37 1,507 (0.9) 3,085 (1.7) 171,732 (97.4) SD: standard deviation. IQR: interquartile range MEDEA: socioeconomic index of one rural category and five urban categories/quintiles. BMI: body mass index Mothers exposed to drugs varied from 76,064 (43.1% of the lactating mothers) from delivery up to month 2, to 32,475 (21.9%), 17,396 (17.6%) and 20,433 (31.8%) at up to months 4, 6 and 12, respectively. Table 2 includes the most dispensed pharmacological groups over the 12 months analyzed in at least 0.5% of the mothers. We also describe the most frequent drug of each group. Iron (25%), folic acid (15.5%) and analgesics (17.7%) were the most frequently used drugs by breastfeeding mothers. Paracetamol was the most frequent analgesic (90.2% of all analgesics), amoxicillin and fosfomycin were the most frequent antibiotics (90% and 89.4% of their corresponding groups), or ibuprofen the most frequent non-steroidal anti-inflammatory drug (NSAID, 75.6%). Table 2Drug exposure in mothers during the 12 after birthMothers exposed to drugs during all the study periodN = 96,094DrugsTotal exposure over the 12 months, n (%)More frequent drug, n (%*)Oral iron44,102 (25.0)Ferrous sulfate, 31,406 (71.2)Analgesics31,102 (17.7)Paracetamol, 28,068 (90.2)Folic acid27,396 (15.5)Folic acid, 27,396 (100.0)Beta-lactam antibacterials25,536 (14.5)Amoxicillin, 22,984 (90.0)NSAID24,114 (13.7)Ibuprofen, 18,224 (75.6)Vitamin B1222,604 (12.8)Cyanocobalamin, 22,604 (100.0)Gynecological anti-infectives/antiseptics6,473 (3.7)Clotrimazole (topical), 3,784 (58.5)Other antibacterials5,975 (3.4)Fosfomycin, 5,340 (89.4)Systemic antihistamines5,323 (3.0)Cetirizine, 1,855 (34.8)Heparins5,107 (2.9)Enoxaparin, 3,574 (70.0)Thyroid hormones3,723 (2.1)Levothyroxine, 3,722 (100.0)Beta-2-adrenoceptor agonists, inhaled3,172 (1.8)Salbutamol, 2,176 (68.6)Proton pump inhibitors2,902 (1.7)Omeprazole, 2,716 (93.4)Macrolides2,295 (1.3)Azithromycin, 1,062 (46.3)Glucocorticoids inhaled2,136 (1.2)Budesonide, 1,548 (72.5)Anxiolytics, hypnotics and sedatives1,880 (1.1)Diazepam, 683 (36.3)H2 – receptor antagonists1,804 (1.0)Ranitidine, 1,766 (97.9)Other systemic hormonal preparations, excluding sex hormones and insulins1,656 (0.94)Prednisone, 1,117 (67.5)SSRI antidepressants1,645 (0.93)Sertraline, 457 (27.8)Laxatives1,632 (0.93)Ispaghula, 1,041 (63.8)Beta-blockers1,586 (0.9)Labetalol, 1,409 (88.8)Other beta-lactam antibacterials1,532 (0.87)Cefuroxime, 971 (63.4)Quinolones1,455 (0.83)Ciprofloxacin, 1,088 (74.8)Other vitamins1,162 (0.66)Cholecalciferol, 1,041 (89.6)*% calculated on the overall exposure of the groupNSAID: non-steroidal anti-inflammatory drugs. SSRI: selective-serotonin reuptake inhibitors Drug exposure in mothers during the 12 after birth *% calculated on the overall exposure of the group NSAID: non-steroidal anti-inflammatory drugs. SSRI: selective-serotonin reuptake inhibitors Figure 3 includes the 10 most frequent pharmacological groups dispensed at the four time-cuts analyzed. The most common ones at month 2 were iron (23.2%), folic acid (14.7%), vitamin B12 (12%) and analgesics (10.6%). All pharmacological groups decreased their exposure in subsequent time-cuts. In the Supplementary Table S4 we have included all pharmacological groups dispensed in at least 0.5% of the mothers in any of the four time-cuts studied. Frequency of drug exposure at the four time-cuts analyzed (2, 4, 6 and 12 months) NSAID: non-steroidal anti-inflammatory drugs Discussion We studied 176,324 mother-infant pairs with lactation registries during the 12 months after birth to analyze the drug exposure of the mothers during the lactation period. The number of breastfed infants decreased over time after birth and the lactating mothers exposed to drugs also decreased up to 6 months, to further increase from months 7 to 12. As expected, the number of infants receiving breast milk progressively diminished during the first year of life, with a mean duration of 6.2 months, as they usually start food other than milk at month 6, [21, 26] and the mandatory duration of maternity leave in Spain is 16 weeks, [27] hindering the maintenance of exclusive breastfeeding even before the World Health Organization recommendations [26]. In fact, some studies in Spain have reported breastfeeding duration in different cohorts and they also found decrease in the number of infants receiving breast milk, stopping before guidelines recommendations [28–31]. The number of lactating mothers exposed to drugs decreased from month 2 to months 4 and 6, but slightly increased at month 12. The decrease may be caused by the mother’s awareness of the potential harms of drug exposure to lactating infants, [32] whereas the increase from months 6 to 12 could be caused by the reduction of numbers of breastfeeding sessions over time as the infant grows, [29, 31, 33] thus the mothers get exposed to drugs more frequently. Regarding drug exposure, iron and vitamin supplements were the most used drugs by breastfeeding women, mainly during the first 2 months after birth, probably due to continuation since pregnancy or due to postpartum anemia in the case of iron, which is a relatively frequent condition [34–37]. Penicillins were also frequently dispensed during breastfeeding, which might be used for common acute conditions, for instance, mastitis [10, 38]. Although it is not the recommended antibiotic for mastitis, [39–41] amoxicillin was the most widely used, which is safe to treat other common infections during lactation, such as respiratory infections [10]. Other frequent antibiotic in our analysis included fosfomycin, which is indicated for urinary tract infections, and it is reported to be safe both during pregnancy and breastfeeding [4, 10]. Analgesics, mainly paracetamol, and NSAID, mainly ibuprofen, were also commonly used and increased from month 6 to 12, probably related to the decrease of breast milk feedings over time. Both ibuprofen and paracetamol are safe analgesic during breastfeeding [10]. Also some drugs for prevalent respiratory conditions were frequently used, such as inhalers or antihistamines, most being compatible with breastfeeding [4, 10]. Information on drug exposure during pregnancy from different populations is available in the literature, whereas data on breastfeeding remain limited. Palmsten et al. recently reported drug exposure in 4,198 lactating mothers at 2, 4 and 6 months after birth identifying progestin contraceptives (19.1%), or selective-serotonin reuptake inhibitors (SSRI) antidepressants (8.8%) as most frequent, together with some antibacterials and NSAID, as in our study [15]. [42] A Finnish register-based study by observed a decline throughout pregnancy and a rebound in lactation for several drugs, except for antiepileptics [17]. Other studies reported frequent use of central nervous system medications, paracetamol or ferrous sulphate, [42] or analgesics, vitamins, iron and laxatives [43]. Campbell et al. analyzed drug exposures from the Utah MotherToBaby service; 34.2% involved breastfeeding, though exposures were not clearly distinguished by pregnancy or lactation [44]. Other studies focused on antidepressants. Legget et al. included 32,662 women reporting 1.8% of exposure to antidepressants [16]. Gorman et al. found that SSRI-exposed mothers were less likely to initiate breastfeeding [45]. Jordan et al. found lower breastfeeding rates among pregnant women [46]. In summary, apart from Palmsten et al. and Lutz et al., few cohort studies have analyzed drug exposure during lactation. Both studies reported mothers’ drug use at different time-cuts during the lactation period, finding similar frequent drugs to those reported in our study. In our setting, breastfeeding is routinely recorded in the infants’ EHR, making it necessary to use mother-infant linked information to study mothers’ drug exposure. The potential limitations of using this approach should be considered. The first limitation could be the misclassification of lactation status, which is collected during the routine visits during childhood [21]. Thus, a second limitation in our data source could be the inability to distinguish between exclusive breastfeeding and mixed feeding (breast milk and other food) in the lactation registries. A third limitation is caused by the information available on the drug dispensing registries in our database, which might have errors incurring in a potential misclassification of start and end of exposure. Another limitation is the potential underreporting of drug exposure due to lack of information on over the counter or non-reimbursed drugs, such as analgesics, antacids, laxatives or supplements. We cannot estimate the medication used by those mothers whose EHR have not been linked to their infants either, also resulting in lower prevalence estimates. Despite these limitations, studies conducted with EHR have several strengths which can help to identify commonly used medications during lactation and prioritize research on their safety, such as the mother-infant linked information, long follow-up and thorough registries including valuable information. Some of the frequently used medications observed in our study have insufficient or inadequate data available regarding the effects on lactating infants, such as SSRI, certain proton-pump inhibitors, or metamizole [10]. Those drugs could be prioritized in future safety studies in lactating mothers. More studies covering the limitations mentioned are still needed, in order to analyze the safety of using drugs during lactation both in the mothers and the infants’ health. Also, more tools to help decision making for prescribers are necessary for the purpose of selecting safe and lactation-compatible drugs. Conclusions Our study analyzed a large mother-infant linked cohort and provided comprehensive information on drug exposure during lactation. The number of lactating and drug-exposed mothers decreased over time in our study, being iron, supplements, analgesics and penicillins the most used drugs. Despite the limitations, our study conducted with EHR add evidence which may help to identify commonly used drugs during lactation and prioritize further studies on their safety. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements The authors want to thank SIDIAP team for their work in maintaining the database and for their help in the data acquisition. Abbreviations Sexual and reproductive healthcare Anatomical Therapeutic Chemical CLASSIFICATION Electronic health records in Catalonia Electronic Health Records United States Food and Drug Administration International Classification of Diseases, 10th revision, Clinical Modification. MEDEA: Socioeconomic index, Mortalidad en áreas pequeñas Españolas y Desigualdades socio-Económicas y Ambientales Non-steroidal anti-inflammatory drug Safe Pharmacological Prescription Information System for Research in Primary Care Selective-serotonin reuptake inhibitors Author contributions Conceptualization: MGS, AGL, RM, CV. Data acquisition: MGS, RM. Data curation: GAR, ACH. Formal analysis: GAR. Funding acquisition: MGS, AGL, MLV, RM, CV. Investigation: all authors. Methodology: all authors. Project administration: MGS, CV. Software: GAR, ACH. Resources: all authors. Supervision: MGS, ACH, RM. Validation: all authors. Visualization: GAR, ACH. Writing – original draft: MGS. Writing – review and editing: all authors. Funding This study received funding from the Health Department of the Generalitat de Catalunya, in the 2021 call for the “Strategic Plan for Research and Innovation in Health (PERIS) 2022–2024, Research Projects in Primary Care”, expedient number SLT021/21/000068. Data availability The datasets generated and/or analysed during the current study are not publicly available due to patient privacy and data protection concerns, but they are available from the corresponding author on reasonable request. All data generated or analysed during this study are included in this published article and its supplementary information files. Declarations Ethics approval and consent to participate The study protocol was approved by the Research Ethics Committee of IDIAPJGol (January 2023, project number 22/102-P). This is a database research study which has been conducted according to the guidelines of the Declaration of Helsinki (Helsinki, Finland 2024) and does not require consent from the people included to participate. The need for consent was waived by the Research Ethics Committee of IDIAPJGol as it is deemed unnecessary according to European legislation (Regulation [EU] 2016/679) and Spanish legislation (Ley Orgánica 3/2018, dated 6 December 2018, de Protección de Datos Personales y garantía de los derechos digitales). Consent for publication Not applicable, as the study did not require consent from people included to participate either. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets generated and/or analysed during the current study are not publicly available due to patient privacy and data protection concerns, but they are available from the corresponding author on reasonable request. All data generated or analysed during this study are included in this published article and its supplementary information files.